Filing Flows › Comparisons › XBIO vs MCRB
Xenetic Biosciences vs Seres Therapeutics: XBIO and MCRB compared
Xenetic Biosciences is the larger company: $661K of revenue in its latest quarter (Q2 2026) against $593K for Seres Therapeutics (Q3 2026). Seres Therapeutics is growing faster (+69% against +12% a year earlier).
Where the money goes: XBIO and MCRB
Xenetic Biosciences (XBIO) · Q2 2026
Xenetic Biosciences, Q2 2026: revenue $661K (+12% year over year), operating margin -147.1%, net loss $930K, operating cash flow −$875K. The chart follows the revenue to costs, profit and cash.
Seres Therapeutics (MCRB) · Q3 2026
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.
| Xenetic Biosciences (XBIO) | Seres Therapeutics (MCRB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $661K | $593K |
| Revenue growth, Y/Y | +12% | +69% |
| Operating margin | -147.1% | n/m |
| Net earnings | −$930K | −$16.3M |
| Net margin | -140.7% | — |
| Operating cash flow | −$875K | −$10.5M |
Questions
Which is bigger, Xenetic Biosciences or Seres Therapeutics?
Xenetic Biosciences is the larger company: $661K of revenue in its latest quarter (Q2 2026) against $593K for Seres Therapeutics (Q3 2026).
Is Xenetic Biosciences or Seres Therapeutics growing faster?
Seres Therapeutics is growing faster (+69% against +12% a year earlier).
More: Xenetic Biosciences earnings · how Xenetic Biosciences makes money · Seres Therapeutics earnings · how Seres Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.